{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:15:46Z","timestamp":1791814546481,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: This study compared choroidal morphological changes, including choroidal vascularity index (CVI) and layer-specific choroidal thickness, between aflibercept 8 mg and faricimab-svoa in treatment-na\u00efve polypoidal choroidal vasculopathy (PCV) and pachychoroid neovasculopathy (PNV). Methods: This retrospective study included 66 eyes treated with aflibercept 8 mg (n = 32) or faricimab-svoa (n = 34). Following three monthly loading injections, a pro re nata regimen was employed for 6 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), pigment epithelial detachment (PED) height, and CVI were assessed. Results: Both groups demonstrated significant improvements in BCVA, CMT, SFCT, and PED height at 6 months (all p &lt; 0.05), with no between-group differences. Dry macula rates were 75.0% and 79.4%, respectively. Faricimab-svoa was associated with a significantly greater CVI increase (0.037 vs. 0.018, p = 0.003), driven by a numerically greater reduction in choriocapillaris\/Sattler\u2019s layer thickness (\u221218.9 \u00b1 16.4 \u03bcm vs. \u221213.8 \u00b1 15.8 \u03bcm, p = 0.153). Conclusions: Both agents achieved comparable functional and anatomical outcomes in treatment-na\u00efve PCV and PNV. Faricimab-svoa was associated with a greater CVI increase, reflecting differential choroidal remodeling. CVI may serve as a biomarker for differentiating the choroidal effects of second-generation anti-VEGF therapies in pachychoroid spectrum disease.<\/jats:p>","DOI":"10.3390\/jcm15114355","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:11:04Z","timestamp":1780593064000},"page":"4355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Choroidal Morphological Changes Between Aflibercept 8 mg and Faricimab-svoa in Treatment-Na\u00efve Polypoidal Choroidal Vasculopathy and Pachychoroid Neovasculopathy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9175-9642","authenticated-orcid":false,"given":"Seongyong","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea"},{"name":"Yeungnam Eye Center, Yeungnam University Hospital, Daegu 42415, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyeon","family":"Seong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea"},{"name":"Yeungnam Eye Center, Yeungnam University Hospital, Daegu 42415, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4140-5015","authenticated-orcid":false,"given":"Min","family":"Sagong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea"},{"name":"Yeungnam Eye Center, Yeungnam University Hospital, Daegu 42415, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"Cheung","year":"2019","journal-title":"Eye"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.18502\/jovr.v18i2.13188","article-title":"Pachychoroid Spectrum Disorders: An Updated Review","volume":"18","author":"Brown","year":"2023","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","article-title":"Pachychoroid pigment epitheliopathy","volume":"33","author":"Warrow","year":"2013","journal-title":"Retina"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): A lesson in the taxonomy of \u2019expanded spectra\u2019\u2014A review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_6","first-page":"111","article-title":"Pachychoroid diseases of the macula","volume":"3","author":"Mrejen","year":"2014","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16204","DOI":"10.1038\/srep16204","article-title":"Pachychoroid neovasculopathy and age-related macular degeneration","volume":"5","author":"Miyake","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","article-title":"Pachychoroid neovasculopathy","volume":"35","author":"Pang","year":"2015","journal-title":"Retina"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","article-title":"Pachychoroid disease: Review and update","volume":"39","author":"Cheung","year":"2025","journal-title":"Eye"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00417-022-05687-6","article-title":"A new insight into pachychoroid diseases: Remodeling of choroidal vasculature","volume":"260","author":"Kishi","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00417-021-05445-0","article-title":"Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid\/drusen perspective","volume":"260","author":"Inoda","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab-svoa up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and Efficacy of Different Doses and Regimens of Faricimab-svoa vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab-svoa in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Iovino, C., Pellegrini, M., Bernabei, F., Borrelli, E., Sacconi, R., Govetto, A., Vagge, A., Di Zazzo, A., Forlini, M., and Finocchio, L. (2020). Choroidal Vascularity Index: An In-Depth Analysis of This Novel Optical Coherence Tomography Parameter. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020595"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1038\/s41598-025-98402-4","article-title":"Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-na\u00efve pachychoroid neovasculopathy","volume":"15","author":"Jeong","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","article-title":"Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy","volume":"9","author":"Jung","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/APO.0000000000000551","article-title":"Optical Coherence Tomography Features for Identifying Posttreatment Complete Polypoidal Regression in Polypoidal Choroidal Vasculopathy","volume":"11","author":"Chaikitmongkol","year":"2022","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40942-025-00665-6","article-title":"Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Na\u00efve neovascular AMD: AI-assisted fluid volume analysis","volume":"11","author":"Cattaneo","year":"2025","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1038\/s41433-024-03214-x","article-title":"The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-na\u00efve neovascular age-related macular degeneration","volume":"38","author":"Chandra","year":"2024","journal-title":"Eye"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41598-024-82746-4","article-title":"Outcomes and predictive factors for fluid resolution following three loading injections of faricimab-svoa for treatment-na\u00efve neovascular age-related macular degeneration","volume":"15","author":"Han","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab-svoa with Treat-and-Extend Dosing in Year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","article-title":"One-year outcomes and safety assessment of faricimab-svoa in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan","volume":"14","author":"Mukai","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00417-025-06849-y","article-title":"One-year functional and structural results of faricimab-svoa for treatment-na\u00efve neovascular age related macular degeneration: An OCT angiography study","volume":"263","author":"Scampoli","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/aos.16797","article-title":"Efficacy of intravitreal faricimab-svoa therapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis","volume":"103","author":"Schou","year":"2025","journal-title":"Acta Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/s41433-025-03980-2","article-title":"One-year outcomes of faricimab-svoa versus aflibercept treatment for polypoidal choroidal vasculopathy: A comparative study","volume":"39","author":"Cho","year":"2025","journal-title":"Eye"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41598-024-52448-y","article-title":"Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept","volume":"14","author":"Sayanagi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21561\/jor.2018.3.1.49","article-title":"Comparing Ranibizumab and Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy","volume":"3","author":"Song","year":"2018","journal-title":"J. Retin."},{"key":"ref_32","first-page":"1859","article-title":"Faricimab-svoa for polypoidal choroidal vasculopathy: Week 16 results from the phase 3b\/4 SALWEEN trial [ARVO abstract]","volume":"66","author":"Lee","year":"2025","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2147\/OPTH.S285257","article-title":"Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration","volume":"15","author":"Elfandi","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schworm, B., Luft, N., Keidel, L.F., Kreutzer, T.C., Herold, T.R., Priglinger, S.G., and Siedlecki, J. (2021). Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy. BMC Ophthalmol., 21.","DOI":"10.1186\/s12886-021-02022-1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: A review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/ATVBAHA.122.318151","article-title":"Angiopoietin-1 Is Required for Vortex Vein and Choriocapillaris Development in Mice","volume":"42","author":"Liu","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2337\/diabetes.53.4.1104","article-title":"Angiopoietin-2 causes pericyte dropout in the normal retina: Evidence for involvement in diabetic retinopathy","volume":"53","author":"Hammes","year":"2004","journal-title":"Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mukai, R., Honjo, J., Tanaka, K., and Sekiryu, T. (2024). Exploring the comparative regressive effects of aflibercept and faricimab-svoa on pigment epithelial detachment. BMC Ophthalmol., 24.","DOI":"10.1186\/s12886-024-03663-8"},{"key":"ref_39","first-page":"5690","article-title":"Greater reduction in pigment epithelial detachment size in TENAYA\/LUCERNE with faricimab-svoa 6.0 mg vs aflibercept 2.0 mg during head-to-head dosing in patients with nAMD [ARVO abstract]","volume":"65","author":"London","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:28:23Z","timestamp":1780594103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114355"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114355","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}